Yidu Tech, Inc.
HHKEX:21582.82
HKD
-0.08
(-2.76%)
ISIN
KYG9845C1069
CUSIP
G9845C106
Return %
Stock
S&P 500
1Y
-50.87
14.20
3Y
-25.20
81.12
5Y
-89.84
68.34
Capital Structure
CNY
•
in mil. unless spec.Working Capital
CNY
•
in mil. unless spec.Growth Rates
CNY
•
in mil. unless spec.Semi-annual Revenue
CNY
•
in mil. unless spec.Semi-annual Earnings Per Share
CNY
•
in mil. unless spec.Semi-annual Dividends Per Share
CNY
•
in mil. unless spec.Company Description
- CEO
- Ji Ming Xu
- Full Time Employees
- 754
- Sector
- Technology services
- Industry
- Information technology services
- Address
- Building 22 Beijing BE China
- IPO Date
- Jan 15, 2021
- Website
- yidutechgroup.com
- Similar Companies
- Business
- Yidu Tech Inc engages in providing healthcare solutions powered by artificial intelligence and big data technology. The company's core products and services include the Big Data Platform and Solutions, which offers medical data intelligence and analytics-driven clinical development, real-world study and evidence, and digital commercialization solutions primarily to pharmaceutical, biotech, and medical device companies; the Life Sciences Solutions segment delivering clinical development support, real-world evidence, digital commercialization solutions, and pharmaceutical product sales; and the Health Management Platform and Solutions segment operating YiduCore, an AI medical brain that extracts, structures and standardizes raw medical data into actionable insights, along with health management platform services, insurance product distribution, personalized digital therapies, and out-of-hospital care services. Yidu Tech operates primarily in China, serving top hospitals, regulators, policymakers, pharmaceutical, and insurance sectors. Founded in 2014 and headquartered in Beijing, the company also integrates its proprietary AI middleware widely across leading Grade III-A hospitals. Recent major developments include Yidu Tech achieving its first full-year profit on adjusted EBITDA in fiscal year 2024 driven by operational efficiencies and business growth, with total revenue reaching RMB 807.1 million and a gross profit margin increase to 42.1%. The company deepened its engagement in AI healthcare innovation by co-building an AI Healthcare Innovation Hub and expanding its client base among top hospitals and policymakers, while continuing to enhance its YiduCore AI medical brain capabilities. Yidu Tech also completed share award grants under its Post-IPO scheme to drive long-term growth and has seen strong revenue growth in its Big Data Platform and Life Sciences segments, reflecting a strategic focus on integrating AI across healthcare services, pharmaceuticals, insurance, and patient care to optimize the healthcare value chain comprehensively. Yidu Tech targets a broad range of healthcare market participants including hospitals, pharmaceutical companies, biotech firms, insurance companies, and regulators, delivering end-to-end AI-powered medical data intelligence and health management services. The company remains focused on expanding industry applications and scaling its AI-driven healthcare ecosystem across China, leveraging proprietary algorithms and strategic partnerships to enhance precision medicine and healthcare accessibility. Its integrated approach combines digital healthcare platforms, real-world evidence, clinical research solutions, and personalized health management tools, positioning Yidu Tech as a leading player in AI-enabled healthcare innovation in the region.